Cytokeratin 8 Level in Age-related Macular Degeneration
Status:
Completed
Trial end date:
2018-04-23
Target enrollment:
Participant gender:
Summary
The investigators will evaluate the concentrations of cytokeratin 8 in aqueous humor in eyes
with exudative age-related macular degeneration (AMD) before therapy with intravitreal
Ranibizumab, and identify associations with visual and anatomical outcome after treatment.
Details
Lead Sponsor:
Gangnam Severance Hospital
Collaborators:
Inje University Konkuk University Novartis Severance Hospital